Human leucocyte antigen class I-redirected anti-tumour CD4+T cells require a higher T cell receptor binding affinity for optimal activity than CD8+T cells

T cell receptor binding affinity governs the functional profile of cancer-specific CD8+T cells

(2015) M. P. Tan et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Antileukemia multifunctionality of CD4+ T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer

(2015) H Fujiwara et al.   LEUKEMIA

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses

(2015) Junko Matsuzaki et al.   Scientific Reports

CD4+CD25- T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model

(2014) A. Chhabra et al.   JOURNAL OF IMMUNOLOGY

Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

(2014) Paul F. Robbins et al.   JOURNAL OF IMMUNOLOGY

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells

(2013) B. J. Cameron et al.   Science Translational Medicine

MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR

(2012) Carolina M. Soto et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies

(2012) Milos Aleksic et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses

(2012) A S Chervin et al.   GENE THERAPY

The molecular determinants of CD8 co-receptor function

(2012) David K. Cole et al.   IMMUNOLOGY

Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+T Cell Responsiveness

(2012) Melita Irving et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Functional differences between low- and high-affinity CD8+T cells in the tumor environment

(2012) Rinke Bos et al.   OncoImmunology

Human MHC Class I-restricted high avidity CD4+T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo

(2012) Shao-An Xue et al.   OncoImmunology

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Rebalancing Immune Specificity and Function in Cancer by T-Cell Receptor Gene Therapy

(2010) Akshata Udyavar et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro

(2010) Swagatam Ray et al.   CLINICAL IMMUNOLOGY

CD8 Controls T Cell Cross-Reactivity

(2010) L. Wooldridge et al.   JOURNAL OF IMMUNOLOGY

Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function

(2010) D. A. Schmid et al.   JOURNAL OF IMMUNOLOGY

Real time detection of peptide–MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability

(2010) Kim M. Miles et al.   MOLECULAR IMMUNOLOGY

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers

(2008) Anna Lissina et al.   JOURNAL OF IMMUNOLOGICAL METHODS